Chorea in the elderly with mutation positive polycythemia vera: A case report

Canadian Journal of Neurological Sciences

Volumn 36, Issue 3, 2009, Pages 370-372

  Kumar, Hrishikesh ^a   Masiowski, Paul ^a   Jog, Mandar ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; JANUS KINASE 2;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CAUSAL ATTRIBUTION; CHOREA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; LABORATORY TEST; MUTATIONAL ANALYSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

EID: 67650624079     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100007149     Document Type: Article

References (23)

1. Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol. 2007 Nov;7(6):360-73.
2. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminars on choreas. Lancet Neurol. 2006 Jul;5(7):589-602.
3. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008 Oct;22(10):1813-7.
4. Finazzi G, Barbui T. The treatment of polcythemia vera: an update in the JAK2 era. Intern Emerg Med. 2007 March;2(1):13-8.
5. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15;110(4):1092-7.
6. Umney WF. Notes on a fatal case of splenomegalic polycythemia. Lancet. 1909;I:1243-5.
7. Bordachzi P. Chorea und polycythemia vera. Prag Med Wochr. 1909;34:253.
8. Cohen AM, Gelvan A, Yarmolovsky A, Djaldetti M. Chorea in polycythemia vera: a rare presentation of hyperviscosity. Blut. 1989 Jan;58(1):47-8.
9. Voiculescu V, Ionescu DA, Lazar G, Alecu C, Predescu C, Popa C, et al. Two cases of choreatic syndrome caused by polycythemia vera. Eur Neurol. 1979;18(2):96-100.
10. Mas JL, Gueguen B, Bouche P, Derouesné C, Varet B, Castaigne P. Chorea and polycythaemia. J Neurol. 1985;232(3):169-71.
11. Bruyn GW, Padberg G. Chorea and polycythaemia. Eur Neurol. 1984;23(1):26-33.
12. Morré HH, van Woerkom TC, Endtz LJ. A case of chorea due to polycythaemia vera. Clin Neurol Neurosurg. 1982;84(2):125-30.
13. Borg-Costanzi JM, Mohr PD, Lewis D. Primary polycythaemia presenting with chorea. Postgrad Med J. 1981 Apr;57(666): 228-31.
14. Nazabal ER, Lopez JM, Perez PA, Del Corral PR. Chorea disclosing deterioration of polycythaemia. Postgrad Med J. 2000 Oct;76:658-9.
15. Midi I, Dib H, Köseoglu M, Afsar N, Günal DI. Hemichorea associated with polycythaemia vera. Neurol Sci. 2006 Dec;27 (6):439-41.
16. Edwards PD, Prosser R, Wells CE. Chorea, polycythaemis, and cyanotic heart disease. J Neurol Neurosurg Psychiatry. 1975 Aug;38(8):729-39.
17. Kim W, Kim JS, Lee KS, Kim YI, Park CW, Chung YA. No evidence of perfusion abnormalities in the basal ganglia of a patient with generalized chorea-ballism and polycythaemia vera: analysis using subtraction SPECT co-registered to MRI. Neurol Sci. 2008 Oct;29(5):351-4.
18. Kotner LM, Tritt JH. Chorea complicating polycythemia vera: report of a case. Ann Int Med.1942;17: 544-8.
19. D'agostino AN, Pease GL, Kernohan FW. Cerebral demyelination associated with polycythemia vera. J Neuropathol Exp Neurol. 1963 Jan;22:138-47.
20. Landolfi R, Di Gennaro L, Falalngo A. Thrombocytosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008 Nov;22(11):2020-8.
21. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenic mechanism and prevention. Best Pract Res Clin Haematol. 2006;19(3):617-33.
22. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008 Aug;22(8):1494-502.
23. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2 V617F and MPL515L/K mutations. Leukemia. 2007;21: 1658-68.